FH-Bind™ Platform

Immune system has the potential for the specific destruction of tumors without toxicity to normal tissues and immuno-oncology is the research and development of a therapy that takes advantage of the body's immune system to fight against cancer. As an excellent and outstanding team in immunomodulatory therapies, Creative Biolabs launches the proprietary FH-Bind™ platform to improve the response rate of immune therapy.

Introduction of FH-Bind™ Platform

Natural human serum albumin (HSA), the predominant protein in blood plasma, exists in the bloodstream. The albumin could accumulate at sites of inflammation, including tumors. A fully human albumin binding construct binds to endogenous HSA in the bloodstream, resulting in significantly enhanced half-life which means remaining longer in the body. It naturally accumulates at sites of inflammation, including tumors, and then is transported to the target tissues.

FH-Bind™ platform provides considerable payload flexibility with asset generation capabilities across major biologic drug classes. Moreover, FH-Bind™ is characterized as fully human, with a human glycosylation profile that can be manufactured using a standard CHO process. The versatile platform can generate a large immune-oncology pipeline, including combinations of two therapeutic cancer products into one synergistic product.

Fig.1 Binding of single-chain single-chain variable domain fragment 637-human serum albumin (scFv637-HSA) to acetylcholine receptor (AChR) in situ at neuromuscular junctions of human intercostal. (Li, 2014)

Characteristics of FH-Bind™ Platform

• FH-Bind™ platform consists of a single, fully human albumin binding antibody fragment that binds to human albumin with high affinity.
• FH-Bind™ platform provides a lock and load opportunity to rapidly develop numerous therapeutic biologics, which are capable of delivering one or two active biologic compounds using flexible, fully human linker peptides.
• FH-Bind™ platform utilizes a linear, flexible rod construct that can bind HSA non-permanently, for better tissue penetration.
• FH-Bind™ leverages human serum albumin to extend therapeutic half-life (pK) and enhance tumor delivery without the need for concentrated, potentially toxic doses.

Services

• FH-Bind™ technology platform

FH-Bind™ is the foundation of a modular, plug-and-play drug development platform with the following distinct advantages:

• Compatibility with many biologic drug classes, including interleukins, growth factors, peptides, and vaccines
• Enhanced pharmacokinetics
• Targeted, directed activity for tumor selectivity
• Increased in vivo efficacy
• Single- or bi-specific mechanisms of action

• FH-Bind™ pipeline platform

Our pipeline platform comprises a lot of cytokine-derived therapeutic candidates, including IL-6 therapeutic candidates.

Creative Biolabs is the best choice for the development of immunomodulatory therapies. With an experienced expert team and deep knowledge of biopharmaceutical drug discovery and development, we launch the proprietary FH-Bind™ technology to empower the development of innovative targeted biologic drugs. If you are interested in the FH-Bind™ platform, please contact us or directly send us an inquiry.

Reference

1. Li, F.; et al. Fusion protein of single-chain variable domain fragments for treatment of myasthenia gravis. Neural Regeneration Research. 2014, 9(8): 851.

For Research Use Only | Not For Clinical Use